

TABLE E-1 Accepted Studies for Aprotinin

Study	No. of Patients		Total Blood Loss* (mL)		Blood Transfusions* (units)		Age* (yr)		No. of Female Patients†		No. of Male Patients†	
	Aprotin in Group	Contr ol Group	Aprotin in Group	Control Group	Aprotin in Group	Control Group	Aprotini n Group	Contro l Group	Aproti nin Group	Contro l Group	Aproti nin Group	Contr ol Group
Lentschener et al. ³	35	37	1935 ± 873	2839 ± 993	1.14 ± 1.57	2.47 ± 1.71	46 ± 9	51 ± 11	17	18	18	19
Amar et al. ⁹	7	3	2319 ± 971	2178 ± 388	3 ± 1	3 ± 3	55 ± 13	55 ± 16	NA	NA	NA	NA
Okubadejo et al. ⁸	40	41	906 ± 97.1	1339 ± 178.5	1.17 ± 0.21	2.06 ± 0.41	50.9 ± 13.5	50.4 ± 12.1	36	37	4	4
Urban et al. ¹	20	18	3628	5181	4 ± 1	6 ± 2	47.3	47.2	NA	NA	NA	NA
Cole et al. ⁷	21	23	545 ± 311.9	929.9 ± 771.7	1.1 ± 1	2.2 ± 1.7	13 ± 4.7	12.2 ± 3.8	NA	NA	NA	NA
Khoshhal et al. ¹⁶	15	28	831	1403	1.54	2.84	14.5	14.1	12	21	3	7
Tayyab et al. ¹⁵	41	41	1324 ± 608	2113 ± 1296	2.73	5.02	47	41	NA	NA	NA	NA
Total	179	191										

*The values are given as the mean and the standard deviation (when available).

†NA = not available.

TABLE E-2 Accepted Studies for Tranexamic Acid

Study	No. of Patients		Total Blood Loss* (mL)		Blood Transfusions* (units)		Age* (yr)		No. of Female Patients		No. of Male Patients	
	Tranexamic Acid Group	Control Group	Tranexamic Acid Group	Control Group	Tranexamic Acid Group	Control Group	Tranexamic Acid Group	Control Group	Tranexamic Acid Group	Control Group	Tranexamic Acid Group	Control Group
Bednar et al. ⁵	14	14	1570.83 ± 1067.4	1963.33 ± 1389.6	4.21 ± 1.53	3.94 ± 3.32	58.3 ± 14.8	60.8 ± 10.6	4	8	10	6
Neilipovitz et al. ¹⁰	22	18	2453 ± 1526	2703 ± 1292	3.5 ± 3.16	5.02 ± 2.17	14.1 ± 2.1	13.7 ± 2.5	10	13	12	5
Sethna et al. ¹³	23	21	1935 ± 873	2839 ± 993	2.46 ± 1.80	3.76 ± 2.87	13.6 ± 1.8	14 ± 2.0	6	8	17	13
Krohn et al. ¹⁴	16	14	1200 ± 353.5	1558 ± 348.5	0.44 ± 1.5	0.21 ± 0.8	49.1 ± 8.8	44.9 ± 15.2	9	9	7	5
Wong et al. ¹¹	38	34	2219.7 ± 653.6	2711.4 ± 881.9	1.05 ± 1.37	2.14 ± 1.92	52.3 ± 5.2	47.6 ± 6.9	25	22	13	12
Kim and Bae ¹²	11	11	859.5 ± 280	1366 ± 333.7	0.65 ± 1.28	1.92 ± 1.26	60.6 ± 7.3	54.2 ± 8.2	7	5	4	6
Shapiro et al. ⁶	16	36	678.12 ± 290	952 ± 508.5	2.17 ± 1.88	3.82 ± 2.87	13.9	14	0	0	16	36
Total	140	148										

*The values are given as the mean and the standard deviation (when available).

TABLE E-3 Accepted Studies for Epsilon-Aminocaproic Acid

Study	No. of Patients		Total Blood Loss* (mL)		Blood Transfusions* (units)		Age*† (yr)		No. of Female Patients†		No. of Male Patients†	
	Epsilon-Aminocaproic Group	Control Group	Epsilon-Aminocaproic Group	Control Group	Epsilon-Aminocaproic Group	Control Group	Epsilon-Aminocaproic Group	Control Group	Epsilon-Aminocaproic Group	Control Group	Epsilon-Aminocaproic Group	Control Group
Urban et al. ¹	17	18	4056	5181	5 ± 2	6 ± 2	46.6	47.2	NA	NA	NA	NA
Amar et al. ⁹	7	3	1829 ± 1305	2178 ± 388	3 ± 3	3 ± 3	53 ± 18	55 ± 16	NA	NA	NA	NA
Florentino-Pineda et al. ¹⁷	28	31	1604 ± 517	2312 ± 994	1.1 ± 1.0	2.1 ± 1.1	14.5 ± 1.6	13.3 ± 1.3	24	28	4	3
Florentino-Pineda et al. ¹⁸	19	17	1391 ± 212	1716 ± 513	1.1 ± 1.0	2.1 ± 1.3	13.5 ± 1.6	14.5 ± 1.3	14	13	5	4
Thompson et al. ¹⁹	27	15	2080 ± 659	3807 ± 1058	1.9 ± 0.9	3.1 ± 1.5	NA	NA	NA	NA	NA	NA
Thompson et al. ¹⁹	16	15	2183 ± 852	3807 ± 1058	1 ± 0.8	3.1 ± 1.5	NA	NA	NA	NA	NA	NA
Thompson et al. ²⁰	61	34	1789 ± 939	3039 ± 1851	1.4 ± 2.5	3.2 ± 4.4	14 ± 2.4	12.3 ± 2.8	NA	NA	NA	NA
Total	175	133										

*The values are given as the mean and the standard deviation (when available).

†NA = not available.

TABLE E-4 Side-Effect Profiles of Antifibrinolytic Agents

	Aprotinin	Tranexamic Acid	Epsilon-Aminocaproic Acid
General			
Fever	X		
Infection	X		
Chest pain	X		
Asthenia	X		
Headache			X
Malaise			X
Hypersensitivity reactions			
Allergic reaction	X		X
Anaphylaxis	X		X
Cardiovascular			
Peripheral ischemia			X
Ventricular fibrillation	X		
Heart arrest	X		
Hemorrhage	X		
Bundle branch block	X		
Heart block	X		
Shock	X		
Pulmonary hypertension	X		
Atrial fibrillation	X		
Hypotension	X	X	X
Myocardial infarct	X		
Atrial flutter	X		
Ventricular extrasystoles	X		
Tachycardia	X		
Bradycardia	X		X
Heart failure	X		
Pericarditis	X		
Peripheral edema	X		
Hypertension	X		
Arrhythmia	X		
Supraventricular tachycardia	X		
Atrial arrhythmia	X		

Gastrointestinal			
Nausea	X	X	X
Constipation	X		
Vomiting	X	X	X
Diarrhea	X	X	X
Liver function tests abnormal	X		
Jaundice	X		
Dyspepsia	X		X
Gastrointestinal hemorrhage	X		
Hematologic and lymphatic			
Thrombosis	X	X	X
Pulmonary embolus	X	X	X
Thrombophlebitis	X		
Deep thrombophlebitis	X		
Anemia	X		
Cerebrovascular accident	X		X
Leukocytosis	X	X	
Thrombocytopenia	X		
Coagulation disorder	X		X
Central retinal artery occlusion			X
Leukopenia		X	
Neurologic			
Delirium			X
Confusion	X		X
Insomnia	X		
Dizziness	X		X
Agitation	X		
Convulsions	X		X
Metabolic and nutritional			
Hyperglycemia	X		
Hypokalemia	X		
Acidosis	X		
Respiratory			
Pneumonia	X		
Pleural effusion	X		

Atelectasis	X		
Dyspnea	X		X
Pneumothorax	X		
Asthma	X		
Hypoxia	X		
Increased cough	X		
Nasal congestion			X
Lung edema	X		
Skin			
Rash			X
Urogenital			
Kidney function abnormal	X		X
Urinary retention	X		
Urinary tract infection	X		
Kidney failure	X		X
Acute kidney failure	X	X	
Kidney tubular necrosis	X		
Dry ejaculation			X
Special senses			
Tinnitus			X
Vision decreased			X
Watery eyes			X
Musculoskeletal			
Creatine phosphokinase increased	X		X
Myalgia			X
Myositis			X
Myopathy			X
Rhabdomyolysis			X
Arthralgias	X		